{"transactions":[{"id":55999,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-05-12T21:00:14.000Z","date":"2023-05-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":2876,"price":146.42,"value":421103.92,"ownership":{"direct":true},"balance_after":28024,"source":{"system":"sec-edgar","filing":"0001415889-23-007908","document":"form4-05122023_050501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923007908/form4-05122023_050501.xml","form_type":"4"}},{"id":57647,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-03-07T22:00:23.000Z","date":"2023-03-05","kind":"tax_withholding","acquired":false,"shares":449,"price":156.06,"value":70070.94,"ownership":{"direct":true},"balance_after":30900,"source":{"system":"sec-edgar","filing":"0001415889-23-004428","document":"form4-03072023_050303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923004428/form4-03072023_050303.xml","form_type":"4"}},{"id":57863,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-03-02T22:08:01.000Z","date":"2023-03-02","kind":"tax_withholding","acquired":false,"shares":810,"price":155.27,"value":125768.7,"ownership":{"direct":true},"balance_after":31349,"source":{"system":"sec-edgar","filing":"0001415889-23-003857","document":"form4-03022023_100349.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923003857/form4-03022023_100349.xml","form_type":"4"}},{"id":57862,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-03-02T22:08:01.000Z","date":"2023-02-28","kind":"tax_withholding","acquired":false,"shares":5762,"price":154.28,"value":888961.36,"ownership":{"direct":true},"balance_after":32159,"source":{"system":"sec-edgar","filing":"0001415889-23-003857","document":"form4-03022023_100349.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923003857/form4-03022023_100349.xml","form_type":"4"}},{"id":58444,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Option (Right to Buy)","published_at":"2023-02-21T23:14:17.000Z","date":"2023-02-21","kind":"exercise","acquired":false,"shares":6370,"price":67.25,"value":428382.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F10","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":67.25,"exercise_date":"2015-02-21","expiration_date":"2024-02-20","underlying":"Common Stock","underlying_shares":6370},"source":{"system":"sec-edgar","filing":"0001415889-23-002946","document":"form4-02212023_110208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002946/form4-02212023_110208.xml","form_type":"4"}},{"id":58443,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Option (Right to Buy)","published_at":"2023-02-21T23:14:17.000Z","date":"2023-02-21","kind":"exercise","acquired":false,"shares":7809,"price":56.93,"value":444566.37,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F10","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":56.93,"exercise_date":"2014-02-21","expiration_date":"2023-02-21","underlying":"Common Stock","underlying_shares":7809},"source":{"system":"sec-edgar","filing":"0001415889-23-002946","document":"form4-02212023_110208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002946/form4-02212023_110208.xml","form_type":"4"}},{"id":58442,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Option (Right to Buy)","published_at":"2023-02-21T23:14:17.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":16205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F9","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,402 on February 16, 2024, 5,402 on February 16, 2025, and 5,401 on February 16, 2026."}],"balance_after":16205,"derivative":{"exercise_price":149.62,"exercise_date":"2024-02-16","expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":16205},"source":{"system":"sec-edgar","filing":"0001415889-23-002946","document":"form4-02212023_110208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002946/form4-02212023_110208.xml","form_type":"4"}},{"id":58441,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:14:17.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":400,"price":151.34,"value":60536.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.15 to $151.42, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":37921,"source":{"system":"sec-edgar","filing":"0001415889-23-002946","document":"form4-02212023_110208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002946/form4-02212023_110208.xml","form_type":"4"}},{"id":58440,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:14:17.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":567,"price":150.78,"value":85492.26,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.10, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":38321,"source":{"system":"sec-edgar","filing":"0001415889-23-002946","document":"form4-02212023_110208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002946/form4-02212023_110208.xml","form_type":"4"}},{"id":58439,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:14:17.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":7646,"price":151.29,"value":1156763.34,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":38888,"source":{"system":"sec-edgar","filing":"0001415889-23-002946","document":"form4-02212023_110208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002946/form4-02212023_110208.xml","form_type":"4"}},{"id":58438,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:14:17.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":6533,"price":150.74,"value":984784.42,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46534,"source":{"system":"sec-edgar","filing":"0001415889-23-002946","document":"form4-02212023_110208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002946/form4-02212023_110208.xml","form_type":"4"}},{"id":58437,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:14:17.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":7780,"price":151.28,"value":1176958.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":53067,"source":{"system":"sec-edgar","filing":"0001415889-23-002946","document":"form4-02212023_110208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002946/form4-02212023_110208.xml","form_type":"4"}},{"id":58436,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:14:17.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":5615,"price":150.71,"value":846236.65,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":60847,"source":{"system":"sec-edgar","filing":"0001415889-23-002946","document":"form4-02212023_110208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002946/form4-02212023_110208.xml","form_type":"4"}},{"id":58435,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:14:17.000Z","date":"2023-02-21","kind":"exercise","acquired":true,"shares":6370,"price":67.25,"value":428382.5,"ownership":{"direct":true},"balance_after":66462,"source":{"system":"sec-edgar","filing":"0001415889-23-002946","document":"form4-02212023_110208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002946/form4-02212023_110208.xml","form_type":"4"}},{"id":58434,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:14:17.000Z","date":"2023-02-21","kind":"exercise","acquired":true,"shares":7809,"price":56.93,"value":444566.37,"ownership":{"direct":true},"balance_after":60092,"source":{"system":"sec-edgar","filing":"0001415889-23-002946","document":"form4-02212023_110208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002946/form4-02212023_110208.xml","form_type":"4"}},{"id":58433,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:14:17.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":5074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":52283,"source":{"system":"sec-edgar","filing":"0001415889-23-002946","document":"form4-02212023_110208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002946/form4-02212023_110208.xml","form_type":"4"}},{"id":58432,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & PRES GLOBAL ALLERG AESTH"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:14:17.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":6546,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":47209,"source":{"system":"sec-edgar","filing":"0001415889-23-002946","document":"form4-02212023_110208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002946/form4-02212023_110208.xml","form_type":"4"}},{"id":66338,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-05-13T21:46:12.000Z","date":"2022-05-11","kind":"tax_withholding","acquired":false,"shares":2876,"price":152.09,"value":437410.84,"ownership":{"direct":true},"balance_after":40663,"source":{"system":"sec-edgar","filing":"0001179110-22-003023","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022003023/edgar.xml","form_type":"4"}},{"id":66480,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-05-09T21:15:04.000Z","date":"2022-05-07","kind":"tax_withholding","acquired":false,"shares":234,"price":152.83,"value":35762.22,"ownership":{"direct":true},"balance_after":43539,"source":{"system":"sec-edgar","filing":"0001179110-22-002934","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022002934/edgar.xml","form_type":"4"}},{"id":69385,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-03-07T22:01:43.000Z","date":"2022-03-06","kind":"tax_withholding","acquired":false,"shares":355,"price":150.56,"value":53448.8,"ownership":{"direct":true},"balance_after":43773,"source":{"system":"sec-edgar","filing":"0001179110-22-002018","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022002018/edgar.xml","form_type":"4"}},{"id":69384,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-03-07T22:01:43.000Z","date":"2022-03-05","kind":"tax_withholding","acquired":false,"shares":448,"price":150.56,"value":67450.88,"ownership":{"direct":true},"balance_after":44128,"source":{"system":"sec-edgar","filing":"0001179110-22-002018","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022002018/edgar.xml","form_type":"4"}},{"id":69762,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-03-02T22:04:51.000Z","date":"2022-03-02","kind":"tax_withholding","acquired":false,"shares":810,"price":147.69,"value":119628.9,"ownership":{"direct":true},"balance_after":44576,"source":{"system":"sec-edgar","filing":"0001179110-22-001925","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001925/edgar.xml","form_type":"4"}},{"id":69848,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-03-01T23:15:22.000Z","date":"2022-02-25","kind":"tax_withholding","acquired":false,"shares":2840,"price":149.54,"value":424693.6,"ownership":{"direct":true},"balance_after":45386,"source":{"system":"sec-edgar","filing":"0001179110-22-001842","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001842/edgar.xml","form_type":"4"}},{"id":70211,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Option(Right to Buy)","published_at":"2022-02-22T22:42:52.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":24080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,027 on February 17, 2023, 8,027 on February 17, 2024, and 8,026 on February 17, 2025."}],"balance_after":24080,"derivative":{"exercise_price":144.54,"exercise_date":"2023-02-17","expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":24080},"source":{"system":"sec-edgar","filing":"0001179110-22-001520","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001520/edgar.xml","form_type":"4"}},{"id":70210,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T22:42:52.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":5727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022."}],"balance_after":48226,"source":{"system":"sec-edgar","filing":"0001179110-22-001520","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001520/edgar.xml","form_type":"4"}},{"id":71729,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Option (right to buy)","published_at":"2022-02-08T22:13:24.000Z","date":"2022-02-07","kind":"exercise","acquired":true,"shares":4184,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":47.27,"exercise_date":"2013-02-17","expiration_date":"2022-02-17","underlying":"Common Stock","underlying_shares":4184},"source":{"system":"sec-edgar","filing":"0001179110-22-000922","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022000922/edgar.xml","form_type":"4"}},{"id":71728,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-08T22:13:24.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":2396,"price":141.17,"value":338243.32,"ownership":{"direct":true},"balance_after":42499,"source":{"system":"sec-edgar","filing":"0001179110-22-000922","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022000922/edgar.xml","form_type":"4"}},{"id":71727,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-08T22:13:24.000Z","date":"2022-02-07","kind":"grant","acquired":true,"shares":4184,"price":47.27,"value":197777.68,"ownership":{"direct":true},"balance_after":44895,"source":{"system":"sec-edgar","filing":"0001179110-22-000922","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022000922/edgar.xml","form_type":"4"}},{"id":73594,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-01-05T22:27:09.000Z","date":"2021-12-31","kind":"tax_withholding","acquired":false,"shares":10336,"price":135.93,"value":1404972.48,"ownership":{"direct":true},"balance_after":40711,"source":{"system":"sec-edgar","filing":"0001179110-22-000262","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022000262/edgar.xml","form_type":"4"}},{"id":81655,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-08-25T22:08:59.000Z","date":"2021-08-23","kind":"sale","acquired":false,"shares":5057,"price":120,"value":606840.0,"ownership":{"direct":true},"balance_after":51047,"source":{"system":"sec-edgar","filing":"0001179110-21-008422","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021008422/edgar.xml","form_type":"4"}},{"id":87796,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-05-12T21:04:50.000Z","date":"2021-05-11","kind":"tax_withholding","acquired":false,"shares":2887,"price":116.22,"value":335527.14,"ownership":{"direct":true},"balance_after":56104,"source":{"system":"sec-edgar","filing":"0001179110-21-005245","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021005245/edgar.xml","form_type":"4"}},{"id":87972,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-05-11T21:05:00.000Z","date":"2021-05-07","kind":"tax_withholding","acquired":false,"shares":234,"price":116.08,"value":27162.72,"ownership":{"direct":true},"balance_after":58991,"source":{"system":"sec-edgar","filing":"0001179110-21-005196","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021005196/edgar.xml","form_type":"4"}},{"id":88547,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Option (right to buy)","published_at":"2021-05-05T20:23:37.000Z","date":"2021-05-03","kind":"exercise","acquired":false,"shares":4184,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":41.39,"exercise_date":"2013-08-05","expiration_date":"2021-08-05","underlying":"Common Stock","underlying_shares":4184},"source":{"system":"sec-edgar","filing":"0001179110-21-004898","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021004898/edgar.xml","form_type":"4"}},{"id":88546,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-05-05T20:23:37.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":4184,"price":112.4,"value":470281.6,"ownership":{"direct":true},"balance_after":59225,"source":{"system":"sec-edgar","filing":"0001179110-21-004898","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021004898/edgar.xml","form_type":"4"}},{"id":88545,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-05-05T20:23:37.000Z","date":"2021-05-03","kind":"exercise","acquired":true,"shares":4184,"price":41.39,"value":173175.76,"ownership":{"direct":true},"balance_after":63409,"source":{"system":"sec-edgar","filing":"0001179110-21-004898","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021004898/edgar.xml","form_type":"4"}},{"id":91498,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-03-09T22:26:29.000Z","date":"2021-03-07","kind":"tax_withholding","acquired":false,"shares":123,"price":106.7,"value":13124.1,"ownership":{"direct":true},"balance_after":59225,"source":{"system":"sec-edgar","filing":"0001179110-21-003128","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021003128/edgar.xml","form_type":"4"}},{"id":91497,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-03-09T22:26:29.000Z","date":"2021-03-06","kind":"tax_withholding","acquired":false,"shares":356,"price":106.7,"value":37985.2,"ownership":{"direct":true},"balance_after":59348,"source":{"system":"sec-edgar","filing":"0001179110-21-003128","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021003128/edgar.xml","form_type":"4"}},{"id":91496,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-03-09T22:26:29.000Z","date":"2021-03-05","kind":"tax_withholding","acquired":false,"shares":448,"price":105.65,"value":47331.2,"ownership":{"direct":true},"balance_after":59704,"source":{"system":"sec-edgar","filing":"0001179110-21-003128","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021003128/edgar.xml","form_type":"4"}},{"id":92101,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-03-03T01:25:11.000Z","date":"2021-03-02","kind":"tax_withholding","acquired":false,"shares":810,"price":108.41,"value":87812.1,"ownership":{"direct":true},"balance_after":60152,"source":{"system":"sec-edgar","filing":"0001179110-21-002588","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002588/edgar.xml","form_type":"4"}},{"id":92772,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Option (right to buy)","published_at":"2021-02-22T23:16:52.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":32298,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,766 on February 18, 2022 10,766 on February 18, 2023, and 10,766 on February 18, 2024."}],"balance_after":32298,"derivative":{"exercise_price":105.92,"exercise_date":"2022-02-18","expiration_date":"2031-02-17","underlying":"Common stock","underlying_shares":32298},"source":{"system":"sec-edgar","filing":"0001179110-21-002043","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002043/edgar.xml","form_type":"4"}},{"id":95954,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-01-05T22:02:17.000Z","date":"2020-12-31","kind":"tax_withholding","acquired":false,"shares":2576,"price":107.15,"value":276018.4,"ownership":{"direct":true},"balance_after":60962,"source":{"system":"sec-edgar","filing":"0001179110-21-000196","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021000196/edgar.xml","form_type":"4"}},{"id":104898,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Option (right to buy)","published_at":"2020-05-12T21:52:43.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":3613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options are exercisable as follows: 1,804 exercisable as of 5/8/2020; 902 as of 3/6/2021; and 907 as of 3/6/2022."}],"balance_after":3613,"derivative":{"exercise_price":65.45,"expiration_date":"2028-03-06","underlying":"Common Stock","underlying_shares":3613},"source":{"system":"sec-edgar","filing":"0001179110-20-005835","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005835/edgar.xml","form_type":"4"}},{"id":104897,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Option (right to buy)","published_at":"2020-05-12T21:52:43.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":3440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options are exercisable as follows: 2,579 exercisable as of 5/8/2020 and 861 as of 3/7/2021."}],"balance_after":3440,"derivative":{"exercise_price":104.04,"expiration_date":"2027-03-06","underlying":"Common Stock","underlying_shares":3440},"source":{"system":"sec-edgar","filing":"0001179110-20-005835","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005835/edgar.xml","form_type":"4"}},{"id":104896,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Option (right to buy)","published_at":"2020-05-12T21:52:43.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":2567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303."}],"balance_after":2567,"derivative":{"exercise_price":123.51,"exercise_date":"2020-05-08","expiration_date":"2026-03-07","underlying":"Common Stock","underlying_shares":2567},"source":{"system":"sec-edgar","filing":"0001179110-20-005835","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005835/edgar.xml","form_type":"4"}},{"id":104895,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Option (right to buy)","published_at":"2020-05-12T21:52:43.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":2017,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303."}],"balance_after":2017,"derivative":{"exercise_price":133.53,"exercise_date":"2020-05-08","expiration_date":"2025-03-16","underlying":"Common Stock","underlying_shares":2017},"source":{"system":"sec-edgar","filing":"0001179110-20-005835","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005835/edgar.xml","form_type":"4"}},{"id":104894,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Option (right to buy)","published_at":"2020-05-12T21:52:43.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":5729,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303."}],"balance_after":5729,"derivative":{"exercise_price":125.82,"exercise_date":"2020-05-08","expiration_date":"2025-02-20","underlying":"Common Stock","underlying_shares":5729},"source":{"system":"sec-edgar","filing":"0001179110-20-005835","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005835/edgar.xml","form_type":"4"}},{"id":104893,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Option (right to buy)","published_at":"2020-05-12T21:52:43.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":6370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303."}],"balance_after":6370,"derivative":{"exercise_price":67.25,"exercise_date":"2020-05-08","expiration_date":"2024-02-21","underlying":"Common Stock","underlying_shares":6370},"source":{"system":"sec-edgar","filing":"0001179110-20-005835","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005835/edgar.xml","form_type":"4"}},{"id":104892,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Option (right to buy)","published_at":"2020-05-12T21:52:43.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":7809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303."}],"balance_after":7809,"derivative":{"exercise_price":56.93,"exercise_date":"2020-05-08","expiration_date":"2023-02-21","underlying":"Common Stock","underlying_shares":7809},"source":{"system":"sec-edgar","filing":"0001179110-20-005835","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005835/edgar.xml","form_type":"4"}},{"id":104891,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Option (right to buy)","published_at":"2020-05-12T21:52:43.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":4184,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303."}],"balance_after":4184,"derivative":{"exercise_price":47.27,"exercise_date":"2020-05-08","expiration_date":"2022-02-17","underlying":"Common Stock","underlying_shares":4184},"source":{"system":"sec-edgar","filing":"0001179110-20-005835","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005835/edgar.xml","form_type":"4"}},{"id":104890,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Option (right to buy)","published_at":"2020-05-12T21:52:43.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":4184,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303."}],"balance_after":4184,"derivative":{"exercise_price":41.39,"exercise_date":"2020-05-08","expiration_date":"2021-08-05","underlying":"Common Stock","underlying_shares":4184},"source":{"system":"sec-edgar","filing":"0001179110-20-005835","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005835/edgar.xml","form_type":"4"}},{"id":104889,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-05-12T21:52:43.000Z","date":"2020-05-11","kind":"grant","acquired":true,"shares":23196,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These securities represent restricted stock units granted under the AbbVie 2013 Incentive Stock Program. They vest in four equal annual increments on the date of grant and include the right to have stock withheld for tax purposes. The options are exercisable as follows: 2,579 exercisable as of 5/8/2020 and 861 as of 3/7/2021."}],"balance_after":63538,"source":{"system":"sec-edgar","filing":"0001179110-20-005835","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005835/edgar.xml","form_type":"4"}},{"id":104888,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-05-12T21:52:43.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":37903,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 16,457 restricted stock units of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. restricted stock units was calculated pursuant to an equity award conversion ratio of 2.303. The restricted stock units vest as follows: 5,194 on 12/31/2020; 1,633 on 3/2/2021; 903 on 3/5/2021; 717 on 3/6/2021; 247 on 3/7/2021; 470 on 5/7/2021; 20,844 on 12/31/2021; 1,633 on 3/2/2022; 903 on 3/5/2022; 716 on 3/6/2022; 470 on 5/7/2022; 1,633 on 3/2/2023; 905 on 3/5/2023; and 1,635 on 3/2/2024."}],"balance_after":40342,"source":{"system":"sec-edgar","filing":"0001179110-20-005835","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005835/edgar.xml","form_type":"4"}},{"id":104887,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11496,"kind":"person","name":"Strom Carrie C","position":1,"cik":"0001811896","reported_name":"Strom Carrie C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Pres Global Allerg Aesth"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-05-12T21:52:43.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":2439,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 2,816 shares of Allergan plc common stock in connection with its acquisition by AbbVie Inc. Allergan shareholders received 0.8660 AbbVie shares for each Allergan share (based on the closing price of AbbVie's common stock of $84.22 on May 7, 2020)."}],"balance_after":2439,"source":{"system":"sec-edgar","filing":"0001179110-20-005835","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005835/edgar.xml","form_type":"4"}}]}